The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Featured:
Currently, there are no therapies approved for systemic amyloid light-chain (AL) amyloidosis, a plasma cell disorder characterized by deposition of insoluble amyloid fibrils into tissues and organs. This deposition leads to progressive organ damage, with the heart, kidney, and liver being the most commonly affected organs.
Treatment strategies approved for multiple myeloma (MM) are often used for patients with AL amyloidosis. The combination of cyclophosphamide (C), bortezomib (V), and dexamethasone (d; CVd), represents the standard treatment for newly diagnosed patients. However, regimens used for patients with MM are often more toxic in patients with AL amyloidosis, thus more tolerable and effective therapies are needed.
Daratumumab (DARA), an anti-CD38 monoclonal antibody, has proven efficacious, with a manageable safety profile and no reported cardiac or renal toxicities in newly diagnosed and relapsed MM. CD38 is expressed on AL amyloidosis plasma cells and preliminary studies of DARA monotherapy in relapsed AL amyloidosis have shown overall hematologic response rates ≥ 59% without cardiac or renal toxicities.
The phase III ANDROMEDA study (NCT03201965) is designed to compare the combination of the subcutaneous (SC) formulation of DARA with CVd to CVd alone in patients with newly diagnosed AL amyloidosis. This randomized phase is preceded by a safety run-in phase; if no new safety signals are observed in the safety run-in phase (of DARA SC + CVd), approximately 360 patients will be randomized to receive CVd, with or without DARA SC. Here, we report a summary of the results of the safety run-in phase of the study that have been recently published in Blood by Giovanni Palladini and colleagues.1
Table 1. Patient characteristics1
FLC, free light-chain *The classification by cardiac stage, per the modified Mayo Staging system, was based on two risk factors: N-terminal pro-brain natriuretic peptide (NT-proBNP; > 332 ng/L) and high sensitivity cardiac troponin (> 54 ng/L). Based on this system, patients were classified in stage I (no factors), stage II (one risk factor), stage IIIa (two risk factors with NT-proBNP levels ≤ 8,500 ng/L), and stage IIIb (two risk factors with NT-proBNP levels > 8,500 ng/L) |
|
Characteristic |
Patients (N = 28) |
---|---|
Median age, years (range) ≥ 65 years, n (%) |
67.5 (35─83) 16 (57) |
Median time from diagnosis, days (range) |
59.5 (15─501) |
FLC isotype, n (%) Lambda Kappa |
21 (75) 7 (25) |
Immunoglobulin heavy-chain expression, n (%) IgG IgA |
10 (37) 8 (29.6) 2 (7.5) |
Involved organs (˃ 50% of patients), median (range) ≥ 2 organs, n (%) Kidney, n (%) Heart, n (%) |
2 (1─4) 19 (67.9) 19 (67.9) 17 (60.7) |
Mayo Clinic cardiac stage*, n (%) I II IIIa IIIb |
6 (21.4) 16 (57.1) 5 (17.9) 1 (3.6) |
Median treatment cycles, (range) |
16 (1─23) |
Median duration of treatment, months (range) |
15.1 (0.2─20.1) |
At the median follow-up of 17.6 months (1.3–20.4), 25 patients (89%) received > 6 cycles of treatment. Of these, 3 patients received all 6 cycles of DARA SC plus CVd without DARA SC maintenance, while 22 patients (67%) received DARA SC maintenance (> 6 treatment cycles). At the clinical cut-off (July 23, 2019), 13 patients (46%) discontinued treatment and nine patients (32%) underwent elective ASCT.
The most common (≥ 50%) any-grade treatment-emergent adverse events (TEAEs) included diarrhea (67.9%), fatigue (53.6%), and peripheral edema (50%). Grade 3/4 TEAEs observed in more than 15% of patients were fatigue (21.4%) and lymphopenia (17.9%). TEAEs related to DARA have been observed in 75% of patients. All grade cardiac and renal/urinary TEAEs observed in ˃ 5% of patients are reported in Table 2.
Table 2. All grade cardiac and renal/urinary TEAEs (˃ 5%)1
TEAEs, treatment-emergent adverse events |
|
All grade TEAEs |
Patients, n (%) |
---|---|
Cardiac Palpitations |
2 (7%) |
Renal/urinary Pollakiuria Acute kidney injury Hematuria Renal impairment Urinary retention |
4 (14%) 3 (11%) 2 (7%) 2 (7%) 2 (7%) |
Serious TEAEs (n = 12; 43%) included fall (11%), acute kidney injury (11%), pneumonia (7%), cellulitis (7%). One patient (4%) experienced an infusion-related reaction (IRR). Five deaths have occurred, three as a result of complications of ASCT and two due to progression of amyloidosis-related organ dysfunction.
Overall best responses, at a median follow-up of 17.6 months, are reported in Table 3.
Table 3. Patient outcomes1
aCR, amyloidosis complete response; mCR, modified CR; NR, not reached; ORR, overall response rate; PR, partial response; VGPR, very good partial response *At a median follow-up of 17.6 months, all patients with an aCR or mCR remained in hematologic remission. |
|
Parameter |
Patients (N = 28) |
---|---|
ORR aCR + mCR VGPR or better PR or better 1 month 3 months 6 months |
96% 54% 82%
71% 79% 61% |
Median time to first response, days (range) PR or better VGPR aCR + mCR |
9 (7─85) 19 (7─339) 85 (29─179) |
Median duration of aCR + mCR* |
NR |
Overall organ response rate Heart (n = 17) Kidney (n = 18) Liver (n = 4) |
64% 53% 83% 50% |
Median time to organ response, days (range) Cardiac (n = 9) Renal (n = 15) Hepatic (n = 2) |
114 (29─561) 57 (29─449) 330 (321─338) |
Of the 9 patients who underwent ASCT, 1 was in CR prior to transplant. Currently, there are six patients evaluable for post-ASCT hematologic response, of whom four deepened their response.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content